Isis Pharmaceuticals earns $3.5m in milestone payment from Biogen Idec
IISIS-SMNRxis designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. As per the terms of January 2012 agreement,
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
Rigosertib inhibits phosphoinositide 3-kinase and polo-like kinase, the two important cellular signaling pathways frequently activated in cancer cells. The patients who failed previous therapy with hypomethylating agents such